KPL Pharma

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, and developing therapeutic medicines for patients with debilitating diseases with significant unmet medical need. The company's lead product, Arcalyst (rilonacept), is FDA-approved for the treatment of recurrent pericarditis and is being commercialized in the United States. Kiniksa's pipeline includes several clinical-stage assets, such as vixarelimab (KPL-716) and mavrilimumab (KPL-301), which target various inflammatory and autoimmune pathways. The company utilizes a disciplined approach to asset selection, focusing on validated biological pathways and rapid clinical proof-of-concept. Headquartered in Bermuda with significant operations in the United States, Kiniksa is positioned as a leader in the development of targeted immune-modulating therapies.